Company intelligence / Profile preview

TheraTarget

Salt Lake City, Utah, United States

Ownership: Private
Employees: ~2
Development stage: Other

Overview

TheraTarget has developed a patented polymer-drug conjugate platform showing promise in preclinical animal models of ovarian and pancreatic cancer; demonstrated improved drug delivery efficacy and synergistic anti-tumor effects in vitro, but no human clinical data reported yet[1][3][4].

Therapeutic areas: Oncology
Modalities: Polymer-drug conjugateSmall molecule
Industry: Biotech

Drug pipeline

1 asset

cyclopamine

Unknown

Partnerships

Alliance Foundation Trials LLC

Beyond the preview

Go deeper on TheraTarget.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraTarget.

Explore the full profile